Induction of uterine adenomyosis by pituitary grafting and retardation of its development by bromocriptine-mesilate (CB-154) in BALB/c mice.
Development of uterine adenomyosis was examined in BALB/c mice. Anterior pituitary (AP) isografting at 8 weeks of age significantly increased the incidence of adenomyosis in mice by 36 weeks of age as compared to that in control mice bearing no AP isograft. However, in mice with AP grafting, daily administration of 0.2 mg bromocriptine-mesilate (CB-154) between 4 and 8 weeks of age decreased the incidence of adenomyosis at 36 weeks of age to the level of control mice. These results suggest that in mice AP grafting stimulates the development of adenomyosis and that pretreatment with CB-154 during youth can suppress the development.
Mori
T
T
Zoological Institute, Faculty of Science, University of Tokyo, Japan.
Kawashima
S
S
Nagasawa
H
H
D000236:Adenoma / Q000188:drug therapy / Q000473:pathology*; D000818:Animals; D001835:Body Weight; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size; D010903:Pituitary Gland, Anterior / Q000502:physiology*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology*; D014599:Uterus / Q000473:pathology
D001971:Bromocriptine